drugset / Trial / NCT06764017
CHiR Therapy for Elderly DLBCL Intolerant to Chemo
NaSingle-groupOpen-labelTreatment
Summary
The objective of exploring the application of CHiR is to evaluate its therapeutic efficacy and safety in newly diagnosed elderly patients with diffuse large B-cell lymphoma (DLBCL) aged 70 and above, and to investigate the genetic subtypes that may benefit from CHiR. The primary endpoint is the complete remission rate (CRR) at the end of 8 cycles.
Timeline
- Start
- 2025-02-01
- Primary completion
- 2026-12-31
- Completion
- 2027-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | — | — |
| Subject | Tucidinostat | Small molecule | — | — |
| Subject | Zanubrutinib | Small molecule | — | — |